Predictive biomarkers for HER2-positive breast cancer recurrence by Single Cell Precision
The only panel specifically for HER2-positive recurrence that can be taken prior to adjuvant therapy
Will my cancer come back?
Thousands of women lay awake at night with the uncertainty that their cancer might come back.
HER2-positive breast cancer accounts for 20% of breast cancers. It is faster, more aggressive, and has a high chance of recurrence.
Fear of cancer recurrence decreases overall quality of life
Fear of cancer recurrence (FCR) is incredibly common, with some studies finding that ~85% of survivors experience FCR at some point after treatment.
FCR's effects on quality of life include nervousness, poor sleep, inability to concentrate, irritability, difficulties with intimacy, losing enjoyment in previously enjoyed activities, inabilities to do daily activities or hobbies, and more.
89%
Would voluntarily choose to take an early detection and predictive test for cancer recurrence.
88%
Stated that this predictive information would significantly improve their life.
Peace of mind for 70% of survivors
Statistically, 30% of HER2-positive breast cancer cases will recur after treatment.
A predictor of recurrence could give 70% of HER2-positive breast cancer survivors the peace of mind of knowing it won’t.
Beyond just knowing
Even if fated to recur, forewarning of recurrence gives both patient and clinician insight for a treatment plan and an opportunity to prepare.
Clinicians
Clinicians are armed with actionable insight. A prediction of recurrence can give clinicians a head start on a treatment plan or intervention.
Patients
Patients are armed with agency. Patients who are informed about their cancer recurrence risk often experience a heightened sense of agency, which can motivate them to adopt healthier lifestyles.
The only panel specifically for HER2-positive breast cancer recurrence that can be taken prior to adjuvant therapy
Once a breast tumour is resected, it undergoes molecular diagnostics to determine the breast cancer subtype, from which treatment strategies are determined. The patient tumour material used for diagnostic purposes can also be used in our device to predict recurrence without any additional material, enabling uninterrupted execution of the clinical diagnostic workflow.
As a result, even prior to treatment, our device can predict whether a woman's breast cancer will recur. This critical information can be used to influence therapeutic decisions made by the oncologists and allow the care team to strategize recurrence prevention.
How the biomarker is used
Our path to market
With a strategic focus on securing its intellectual property, we are preparing to transition from R&D to commercialization, including pursuing partnership and licensing opportunities. Our work is in the validation stage and we intend to bring this biomarker panel to market within the next 3 years.
About Us
Single Cell Precision Inc. is a biotechnology company focused on identifying biomarkers for early cancer detection and recurrence prediction.
Amidst a booming cancer diagnostics market driven by the need for early detection and personalized medicine, Single Cell Precision's innovative R&D focuses on discovering early-stage biomarkers, that enable earlier treatment and improved patient outcomes.
Our strategy involves identifying new biomarkers, clinical validation, and commercialization through partnerships with industry leaders.
